全文获取类型
收费全文 | 170891篇 |
免费 | 18080篇 |
国内免费 | 4838篇 |
专业分类
耳鼻咽喉 | 812篇 |
儿科学 | 3418篇 |
妇产科学 | 1716篇 |
基础医学 | 10541篇 |
口腔科学 | 3801篇 |
临床医学 | 19617篇 |
内科学 | 30100篇 |
皮肤病学 | 1606篇 |
神经病学 | 9455篇 |
特种医学 | 3161篇 |
外国民族医学 | 19篇 |
外科学 | 10660篇 |
综合类 | 32397篇 |
现状与发展 | 19篇 |
一般理论 | 29篇 |
预防医学 | 14187篇 |
眼科学 | 3559篇 |
药学 | 22010篇 |
903篇 | |
中国医学 | 19989篇 |
肿瘤学 | 5810篇 |
出版年
2024年 | 643篇 |
2023年 | 3224篇 |
2022年 | 5576篇 |
2021年 | 9061篇 |
2020年 | 9055篇 |
2019年 | 6689篇 |
2018年 | 6309篇 |
2017年 | 7342篇 |
2016年 | 8039篇 |
2015年 | 7194篇 |
2014年 | 13279篇 |
2013年 | 13843篇 |
2012年 | 11451篇 |
2011年 | 11520篇 |
2010年 | 8979篇 |
2009年 | 8064篇 |
2008年 | 7608篇 |
2007年 | 7650篇 |
2006年 | 6613篇 |
2005年 | 5662篇 |
2004年 | 4681篇 |
2003年 | 4062篇 |
2002年 | 3418篇 |
2001年 | 2999篇 |
2000年 | 2372篇 |
1999年 | 2011篇 |
1998年 | 1790篇 |
1997年 | 1550篇 |
1996年 | 1397篇 |
1995年 | 1208篇 |
1994年 | 1154篇 |
1993年 | 999篇 |
1992年 | 988篇 |
1991年 | 823篇 |
1990年 | 730篇 |
1989年 | 717篇 |
1988年 | 649篇 |
1987年 | 522篇 |
1986年 | 491篇 |
1985年 | 622篇 |
1984年 | 536篇 |
1983年 | 294篇 |
1982年 | 406篇 |
1981年 | 298篇 |
1980年 | 284篇 |
1979年 | 197篇 |
1978年 | 160篇 |
1977年 | 151篇 |
1976年 | 116篇 |
1975年 | 77篇 |
排序方式: 共有10000条查询结果,搜索用时 490 毫秒
1.
目的 观察结肠癌HCT116细胞健脾消癌方的条件培养液对HUVEC细胞管腔形成的影响,从PI3K/Akt生物轴调控角度探讨其作用机制。方法 培养HCT116细胞,细胞设3组:对照组,健脾消癌方组(加入15%健脾消癌方含药血清)及人参皂苷Rg3组;制备HCT116细胞健脾消癌方条件培养液(分组及制备方法见实验方法),用条件培养液干预HUVEC(脐静脉内皮细胞,Human Umbilical Vein Endothelial Cells),Matrigel基质胶法检测HCT116细胞健脾消癌方条件培养液对HUVEC小管形成的影响。随后采用蛋白免疫印迹法(Western blot)检测各组HCT116细胞磷脂酰肌醇3-激酶(PI3K)、蛋白激酶B(Akt)、p-Akt、VEGF(血管内皮生长因子,Vascular endothelial growth factor)蛋白表达。最后在结肠癌HCT116荷瘤小鼠中验证健脾消癌方对肿瘤生长速度的影响,并经瘤组织VEGF蛋白表达、CD31免疫组化染色检测肿瘤内血管生成情况。结果 模型组HUVEC细胞管腔形成较空白血清组显著增加(P<0.05);健脾消癌方组及人参皂苷Rg3组较模型组HUVEC细胞管腔形成显著减少(P<0.01)。p-Akt和VEGF蛋白表达水平模型组高于空白血清组(P<0.05),健脾消癌方组及人参皂苷Rg3组显著低于模型组(P<0.01);PI3K、Akt蛋白表达量组间差异无统计学意义。与对照组比较,模型组荷瘤小鼠肿瘤体积显著性增大,瘤组织内VEGF表达、CD31阳性面积显著性增加,差异有统计学意义(P<0.05);与模型组比较,健脾消癌方组及人参皂苷Rg3组荷瘤小鼠肿瘤体积显著减小,瘤组织内VEGF表达、CD31阳性面积降低,差异有统计学意义(P<0.05)。结论 健脾消癌方可抑制肿瘤的血管生成和生长,其作用机制可能与PI3K/Akt生物轴调控VEGF表达有关。 相似文献
2.
目的探讨慢性泪囊炎患者应用鼻内镜下鼻腔泪囊造口术的临床效果及安全性。方法选取2018年1月至2019年12月因慢性泪囊炎于本院接受治疗的46例患者为研究对象,随机分为研究组与对照组,各23例。对照组接受泪囊鼻腔造口治疗,研究组取鼻内镜下鼻腔泪囊造口术治疗,比较两组临床效果、手术指标以及并发症发生情况。结果研究组治疗总有效率高于对照组(P<0.05);研究组术中出血量少于对照组,手术及住院时间均短于对照组(P<0.05);研究组并发症总发生率低于对照组(P<0.05)。结论慢性泪囊炎患者采用鼻内镜下鼻腔泪囊造口术治疗效果显著,并发症较少,安全性较高,值得临床推广应用。 相似文献
3.
4.
《Vaccine》2022,40(42):6048-6054
BackgroundLive vaccines potentially have non-specific effects that protect against other infections than those the vaccines are targeted against. The national vaccination program (NVP) in Finland was changed on September 1st, 2006: before BCG vaccine was given to all newborn babies and afterwards to babies in risk groups only. We used this natural experiment to study the non-specific effects of BCG in the frame of NVP using before-after design.MethodsWe compared the incidence of several outcomes obtained from Finnish health registers between children born between July 1st, 2004, and June 30th, 2006 (BCG-eligible) and an age- and season-matched reference cohort born between July 1st, 2007, and June 30th, 2009 (BCG-non-eligible) using Poisson regression. These cohorts were restricted to full-term children whose parents were born in Finland. Follow-up began at birth and lasted 3 months, which is the scheduled age for DTaP-IPV-Hib vaccination, and from 4 months until first birthday. The outcomes included all infections, pneumonia and injuries as a negative control outcome.ResultsThe incidence rate ratio (IRR) of the BCG-eligible cohort (N = 93,658) compared to BCG-non-eligible cohort (N = 94,712) for hospital-diagnosed infections was 0.89 (95 %Cl 0.86–0.93) for the 3-month follow-up. The decrease was mainly caused by respiratory infections. In 4–12 months follow-up the BCG-eligible had slightly more infections than BCG-non-eligible children (IRR 1.03, 1.01–1.06).ConclusionsBCG vaccination was associated with a lower incidence of all hospital-diagnosed infections during the first three months of life. The difference cannot be attributed to lung tuberculosis, since only few paediatric cases occurred in Finland during 2000s. The disappearance of non-specific effect after administration of an inactivated vaccine is compatible with previous studies. 相似文献
5.
6.
7.
《Transfusion and apheresis science》2022,61(4):103487
When the COVID-19 pandemic hit, blood transfusion services worldwide started collection of convalescent plasma as early as possible, as exemplified by the response in Norway. There were challenges related to donor selection, donor safety, testing for relevant antibodies and indications for and dosing of the convalescent plasma. As more knowledge became available, the product quality was more standardised. Multiple case reports, observational studies and some randomized studies were published during the pandemic, as well as laboratory studies reporting different approaches to antibody testing. The results were conflicting and the importance of convalescent plasma was disputed.Even though there has been strong international collaboration with involvement of many key organisations, we may better prepare for the next pandemic. An even stronger, more formalised collaboration between these organisations could provide more clear evidence of the importance of convalescent plasma, based on the principles of passive immunisation. 相似文献
8.
《The Journal for Nurse Practitioners》2022,18(2):245-247
Transient stress hyperglycemia in the setting of acute myocardial infarction is a frequent phenomenon. Its transient nature should not dissuade the clinician from management of elevated blood glucose in a patient after an ST-elevation myocardial infarction. This case presents an adult patient after an ST-elevation myocardial infarction with transient stress hyperglycemia and the evidence used to identify optimal pharmacologic management and secondary prevention. 相似文献
9.
10.